| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.7K | 7.0% | 0.5% |
| Total Income | 1.7K | 7.0% | 0.5% |
| Expenditure | 1.6K | 6.0% | 1.0% |
| PBT | 81.20 | 46.3% | 0.6% |
| Net Profit | 38.10 | 12.0% | 41.1% |
| OPM | 7.20% | 0.91pp | 0.45pp |
| NPM | 2.25% | 0.49pp | 1.59pp |
| EPS | 0.06 | 0.0% | 33.3% |
Avantor Reports Q2 2026 Results and Increases FY26 Guidance
29 Jul 2026 · 29 Jul, 3:46 pm
Summary
Avantor announced its second quarter 2026 financial results, reporting net sales of $1,692.3 million, a 0.5% increase year-over-year, with a 0.4% organic decline. Net income decreased to $38.1 million, and adjusted EBITDA was $254.3 million with a 15.0% margin. The company generated $142.8 million in free cash flow and has raised its full-year 2026 guidance for organic revenue growth and adjusted EPS, signaling confidence in future performance.
Key Highlights
- 1
Avantor reported net sales of $1,692.3 million for the second quarter of 2026, a reported increase of 0.5% year-over-year.
- 2
The company's net income for Q2 2026 was $38.1 million, with diluted GAAP EPS of $0.06.
- 3
Adjusted EBITDA for the second quarter stood at $254.3 million, representing a 15.0% margin.
- 4
Operating cash flow for the quarter was $178.2 million, and free cash flow was $142.8 million.
- 5
The VWR Distribution and Services segment achieved a 1.7% organic revenue increase in Q2 2026.
- 6
Avantor has increased its fiscal year 2026 guidance for organic revenue growth and adjusted EPS.
- 7
The Bioscience and Medtech Products segment reported net sales of $451.8 million in Q2 2026.
Management Comments
Emmanuel Ligner
Our Revival program is strengthening how we serve our customers, leading to improved business performance. Our second quarter results exceeded our expectations across several key financial metrics, and we generated robust free cash flow, which we used to repay $112.1 million of debt, reinforcing our commitment to strengthen our balance sheet. I’m delighted by the improved performance in our VWR Distribution and Services segment, which returned to positive organic revenue growth more quickly than we anticipated. Also, our Bioscience and Medtech Products segment performed near the high end of our expectations. We continue to focus on creating a better experience for our customers and delivering long-term value for our shareholders.
Informational and educational content only. Not investment advice.